Results for iaf translation from Lithuanian to English

iaf-1 koncentracijos serume tikrinimas
serum igf-1 monitoring

doz keiciama atsizvelgiant iaf-i koncentracijserume.
dose adjustments should be based on serum igf-i levels.

dozė keičiama atsižvelgiant į iaf- i koncentracijąserume.
dose adjustments should be based on serum igf-i levels.

doz keiciama atsizvelgiant iaf-i koncentracij serume.
dose adjustments should be based on serum igf-i levels.

dozė keičiama atsižvelgiant į iaf-i koncentraciją serume.
dose adjustments should be based on serum igf-i levels.

inspektionen för arbetslöshetsförsäkringen, iaf (draudimo nuo nedarbo įstaiga)“.
inspektionen för arbetslöshetsförsäkringen, iaf (the unemployment insurance board)’.

inspektionen för arbetslöshetsförsäkringen, iaf (draudimo nuo nedarbo įstaiga).“
inspektionen för arbetslöshetsförsäkringen (swedish unemployment insurance board).’

iaf-i koncentracija serume turi bti pastoviai tikrinama ir palaikoma amziaus normos ribose, keiciant somavert dozavim.
serum igf-i concentrations should be monitored and maintained within the age-adjusted normal range by adjustment of somavert dosing.

perdozavimo atveju somavert vartojim reikia nutraukti ir jo neatnaujinti, kol iaf-i koncentracija vl taps normali arba didesn uz nustatyt normos rib.
in cases of overdose, administration of somavert should be discontinued and not resumed until igf-i levels return to within or above the normal range.

palankus gydomasis poveikis, pasireiskiantis iaf-i koncentracijos sumazjimu, pagerinanciu paciento klinikin bkl, gali skatinti pacienci vaisingum.
the therapeutic benefits of a reduction in igf-i concentration which results in improvement of the patient 's clinical condition could potentially increase fertility in female patients.

tyrimo pabaigoje (12 savaitę) iaf- i kiekis serume normalizavosi 9, 7%, 38, 5%, 75% ir 82% asmenų, kurie buvo gydomi atitinkamai placebu, somavert 10 mg per parą, 15 mg per parą arba 20 mg per parą.
the serum igf-1 was normalised at the end of the study (week 12) in 9.7%, 38.5%, 75% and 82% of subjects treated with placebo, 10 mg/ day, 15 mg/ day or 20 mg/ day somavert respectively.